{"id":"202104126398","sourceId":"dow-jones","sourceName":"Global News Select","providerName":"Dow Jones","title":"Zentalis Pharmaceuticals in Collaboration Agreement With GlaxoSmithKline","publishedDate":"2021-04-12T07:39:00-05:00","body":[{"type":"p","contentObject":[{"type":"text","content":"\n  By Chris Wack ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Zentalis Pharmaceuticals Inc. said it has entered into a clinical collaboration agreement with GlaxoSmithKline PLC. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Zentalis said it will evaluate the combination of ZN-c3, an oral WEE1 inhibitor product candidate, and Zejula niraparib, GlaxoSmithKline's polymerase PARP inhibitor, in patients with advanced epithelial ovarian cancer. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Zentalis is currently conducting clinical studies with ZN-c3 both as a monotherapy and in combination with certain standard of care therapies. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Under the terms of the non-exclusive collaboration, Zentalis is responsible for conducting the study, with GlaxoSmithKline providing all required doses of niraparib. Zentalis will maintain full ownership of ZN-c3. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Zentalis shares were up 21% to $45.21 in premarket trading. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Write to Chris Wack at chris.wack@wsj.com ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  (END) Dow Jones Newswires","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  April 12, 2021 08:39 ET (12:39 GMT)","gated":false}],"gated":false},{"type":"text","content":"\n\nCopyright (c) 2021 Dow Jones & Company, Inc.","gated":false}]}